Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.84B 3.33B 3.07B 2.88B 5.38B 368B 5.49B 36.63B 14.18B 177B 14.41B 14.1B 616B P/E Ratio 2026 *
16.5x
P/E Ratio 2027 * 13.7x
Enterprise Value 3.84B 3.33B 3.07B 2.88B 5.38B 368B 5.49B 36.63B 14.18B 177B 14.41B 14.1B 616B EV / Sales 2026 *
6.07x
EV / Sales 2027 * 5.38x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day+0.10%
1 week+0.26%
Current month+0.45%
1 month+0.71%
3 months+28.54%
6 months+36.75%
Current year+34.40%
1 week 31.28
Extreme 31.28
31.39
1 month 31.13
Extreme 31.13
31.39
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.48
Extreme 11.485
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.63
Extreme 0.6305
32.56
Manager TitleAgeSince
Chief Executive Officer 65 2023-12-31
Director of Finance/CFO 55 2023-12-31
Compliance Officer 62 2016-02-28
Director TitleAgeSince
Chairman 78 2001-12-31
Director/Board Member 62 2002-09-30
Director/Board Member 65 2015-02-18
Date Insider Type Main position Quantity % Market Cap.
06-02Fiscal year

Chief Technology Officer

3,795 0.0031%
02-16Fiscal year

Head of Human Resources

1,585 0.0013%
01-04Fiscal year

Chief Financial Officer

16,358 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+0.26%+23.46%+169.97% 3.84B
+1.63%-2.74%+17.91%-18.09% 62.21B
+2.50%+4.43%+64.44%+216.37% 59.45B
-0.92%+28.60%+28.60%+28.60% 38.9B
+0.26%+9.80%-55.40%-65.15% 36.4B
+2.94%+1.79%+50.28%-35.26% 29.52B
+2.32%+6.51%+56.62%+76.65% 21.54B
+7.94%-3.78%+78.88%-59.73% 19.7B
+4.52%-0.26%-5.39%+112.81% 16.18B
+0.78%-1.57%+44.59%+98.01% 15.89B
Average +2.23%+1.34%+30.40%+52.42% 30.36B
Weighted average by Cap. +2.00%+1.85%+29.67%+45.93%

Financials

2026 *2027 *
Net sales 632M 548M 506M 474M 885M 60.51B 904M 6.03B 2.33B 29.17B 2.37B 2.32B 101B 713M 619M 570M 534M 999M 68.28B 1.02B 6.8B 2.63B 32.91B 2.68B 2.62B 114B
Net income 238M 207M 190M 178M 333M 22.8B 340M 2.27B 880M 10.99B 894M 875M 38.21B 291M 253M 233M 218M 407M 27.86B 416M 2.78B 1.07B 13.43B 1.09B 1.07B 46.7B
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
26-06-11 31.37 $ +0.10% 1,020,948
26-06-10 31.34 $ 0.00% 960,794
26-06-09 31.34 $ +0.19% 1,350,260
26-06-08 31.28 $ +0.03% 1,589,018
26-06-05 31.27 $ -0.06% 1,534,843
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
31.37USD
Average target price
32.75USD
Spread / Average Target
+4.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CPRX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!